2Sacks FM, The role of high-lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. AM J Cardiol, 2002, 90, 139.
3Volpate S, Leveille SG, Corti MC, et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in order persons with low serum cholesterol. J Am Geriatr Soc, 2001, 49:1142.
4Maron DJ. The epidemiology of low high-density lipoprotein cholesterol in patients with and without coronary artery disease.Am J Cardiol, 2000, 86:11.
5Fuchs M, Hafer A, Munch C, et al. Disruption of the sterol carrier protein 2 gene in mice impairs biliary lipid and hepatic cholesteol metabolism. Hepatology, 2001, 33(6) :1451.
二级参考文献7
1Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol, 2000, 86(Suppl) : 11L-14L.
2Weijenberg MP, Feskens JM, Kromhout D. Total and high density cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up. The Zutphen Elderly Study. Am J Epidemiol, 1996, 143:151-158.
3Weverling-Rinjinsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet,1997,350 : 1119-1123.
4Abott RD, Yano K, Hakim AA, et al. Change in total and high-density lipoprotein cholesterol over 10- and 20- year periods (The Honolulu Heart Progrom). Am J Cardiol, 1998, 82.-172-178.
5Volpato S, Leveille SG, Corti MC, et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc, 2001, 49:1142-1147.
6Chyou PH, Eaker ED. Serum cholesterol concentrations and all-cause mortality in older people. Age and Aging, 2000, 29:69-74.
1Chemin I, Guillaud 0, Queyron PC, et al. Close monitoring ofserum HBV DNA levels and liver enzymes levels is most usefulin the management of patients with occult HBV infection [ J ]. JHepatol,2009,51(4); 824-825.
2Els0e S,AhnstrOm J,Christoffersen C,et al. Apolipoprotein Mbinds oxidized phospholipids and increases the antioxidanteffect of HDL[J]. Atherosclerosis,2012,221 (1) :91-97.
3AIM-HIGH Investigators, Boden WE, Probstfield JL’et al.Niacin in patients with low HDL cholesterol levels receivingintensive statin therapy [J]. N Engl J Med,2011,365(24) :2255-2267.
4He XX,Chang Y,Jiang HJ,et al.Persistent effect of IFNAR-1genetic polymorphism on the long-term pathogenesis of chronicHBV infection [J]. Viral Immunol, 2010,23(3): 251-257.
5Hansen BE,Buster EH,Steyerberg EW,et al. Prediction of theresponse to peg-interferon-alfa in patients with HBeAg positivechronic hepatitis B using decline of HBV DNA during treatment[J]. J Med Virol,2010,82(7) :1135-1142.
6Wang L,Liu H,Ning X,et al. Sequence analysis of the S generegion in HBV DNA from patients positive for both HBsAg andHBsAb tests[J]. Hepatol Res,2010,40( 12) : 1212-1218.
7Shi F, Zhang JY,Zeng Z, et al. Skewed ratios between CD3(+) T cells and monocytes are associated with poor prognosisin patients with HBV-related acute-on-chronic liver failure [J].Biochem Biophys Res Commun, 2010,402( 1 ) ; 30-36.
8Guo H, Zhou T,Jiang D, et al.Regulation of hepatitis B virusreplication by the phosphatidylinositol 3-kinase-akt signaltransduction pathway [ J ].J Virol, 2007,81(18): 10072-10080.
10Zhang Z, Liu X, Chen J,et al.Heparin sulphate D-glucosaminyl3-0-sulfotransferase 3B1 plays a role in HBV replication [J].Virology ,2010,406(2): 280-285.
